SR One is GlaxoSmithKline’s independent corporate healthcare venture capital fund. We invest globally in emerging biotech companies that are focused on drug discovery, development or delivery and have the potential to make products that will have a dramatic benefit to patients.

We have a Team of seven investment professionals, located in the US and UK. As a Team, our experience spans basic science, industry and the market.

We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Our current portfolio includes more than 30 private and public companies and since our founding in 1985, we have invested over $500MM in the biotech space.

UPDATE: As of 11 February 2008, we have moved!
See the 'contact us' page for our updated address. Telephone and fax numbers remain unchanged...